Literature DB >> 18321536

Rapid screen for truncating ATM mutations by PTT-ELISA.

Liutao Du1, Chih-Hung Lai, Patrick Concannon, Richard A Gatti.   

Abstract

Mutations in the ataxia-telangiectasia mutated (ATM) gene are responsible for the autosomal recessive genetic disorder, ataxia-telangiectasia (A-T). Approximately 80% of ATM mutations found in A-T patients results in truncations, which can be detected by Protein Truncation Test (PTT). Conventional PTT uses SDS-PAGE electrophoresis to detect mobility of radiolabeled truncated protein fragments. In this study, we developed a non-radioactive Protein Truncation Test which utilizes an enzyme-linked immunosorbent assay (PTT-ELISA) to detect ATM mutations in eight overlapping fragments. N- and C-terminal epitopes (c-myc and V5, respectively) were introduced into transcription/translation products, which could then be detected by Sandwich ELISA. Using this assay, we screened 9 newly diagnosed A-T patients consecutively. Of the 18 expected mutations, 14 truncating mutations were independently identified by cDNA direct sequencing and/or DNA dHPLC analysis. PTT-ELISA detected all of these 14. Four mutations were novel. The PTT-ELISA provides a rapid method for detecting truncating mutations in large genes and should be considered prior to using more laborious or costly methods, such as direct sequencing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321536     DOI: 10.1016/j.mrfmmm.2008.01.002

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  12 in total

Review 1.  Nonsense-mediated RNA decay regulation by cellular stress: implications for tumorigenesis.

Authors:  Lawrence B Gardner
Journal:  Mol Cancer Res       Date:  2010-02-23       Impact factor: 5.852

2.  Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia.

Authors:  Kotoka Nakamura; Liutao Du; Rashmi Tunuguntla; Francesca Fike; Simona Cavalieri; Tomohiro Morio; Shuki Mizutani; Alfredo Brusco; Richard A Gatti
Journal:  Hum Mutat       Date:  2011-11-09       Impact factor: 4.878

Review 3.  SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models.

Authors:  Richard A Gatti
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

4.  Utility of DNA, RNA, Protein, and Functional Approaches to Solve Cryptic Immunodeficiencies.

Authors:  Margot A Cousin; Matthew J Smith; Ashley N Sigafoos; Jay J Jin; Marine I Murphree; Nicole J Boczek; Patrick R Blackburn; Gavin R Oliver; Ross A Aleff; Karl J Clark; Eric D Wieben; Avni Y Joshi; Pavel N Pichurin; Roshini S Abraham; Eric W Klee
Journal:  J Clin Immunol       Date:  2018-04-18       Impact factor: 8.317

5.  p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.

Authors:  Andrea Prodosmo; Andrea De Amicis; Cecilia Nisticò; Mario Gabriele; Giuliana Di Rocco; Laura Monteonofrio; Maria Piane; Enrico Cundari; Luciana Chessa; Silvia Soddu
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

6.  A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene.

Authors:  Liutao Du; Michael E Jung; Robert Damoiseaux; Gladys Completo; Francesca Fike; Jin-Mo Ku; Shareef Nahas; Cijing Piao; Hailiang Hu; Richard A Gatti
Journal:  Mol Ther       Date:  2013-06-18       Impact factor: 11.454

Review 7.  New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals.

Authors:  Hailiang Hu; Richard A Gatti
Journal:  Curr Opin Allergy Clin Immunol       Date:  2008-12

8.  Gene expression signatures but not cell cycle checkpoint functions distinguish AT carriers from normal individuals.

Authors:  Liwen Zhang; Dennis A Simpson; Cynthia L Innes; Jeff Chou; Pierre R Bushel; Richard S Paules; William K Kaufmann; Tong Zhou
Journal:  Physiol Genomics       Date:  2013-08-13       Impact factor: 3.107

9.  Nonaminoglycoside compounds induce readthrough of nonsense mutations.

Authors:  Liutao Du; Robert Damoiseaux; Shareef Nahas; Kun Gao; Hailiang Hu; Julianne M Pollard; Jimena Goldstine; Michael E Jung; Susanne M Henning; Carmen Bertoni; Richard A Gatti
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

10.  Increased radiation toxicity with germline ATM variant of uncertain clinical significance.

Authors:  Brandon T Mullins; Gaorav Gupta
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.